Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated